Effect of Sacubitril-Valsartan in reducing depression in patients with advanced heart failure.
Background: Depression is highly prevalent in Heart Failure (HF). Treatment with sacubitril/valsartan improved quality of life and survival in HF patients. Aim of the study was to investigate prospectively the effect of sacubitril/valsartan on depression in advanced HF patients in waiting list for h...
| Publicado en: | Journal of Affective Disorders Vol. 272; pp. 132 - 138 |
|---|---|
| Autores principales: | , , , , , , , , , , , , |
| Formato: | research tables/charts Journal Article |
| Publicado: |
Elsevier B.V.
Jul2020
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=143765942&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 143765942 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 01650327 3M9 jtl: Journal of Affective Disorders issn: 01650327 maglogo: N pubinfo: dt: Jul2020 vid: 272 pid: 1004 pub: Elsevier B.V. artinfo: ui: 143765942 143765942 NLM32379604 143765942 10.1016/j.jad.2020.03.158 NLM32379604 143765942 ppf: 132 ppct: 6 formats: tig: atl: Effect of Sacubitril-Valsartan in reducing depression in patients with advanced heart failure. aug: au: Cacciatore, Francesco Amarelli, Cristiano Maiello, Ciro Pratillo, Mariella Tosini, Piera Mattucci, Irene Salerno, Gemma Curcio, Francesco Elia, Francesco Mercurio, Valentina Golino, Paolo Bonaduce, Domenico Abete, Pasquale affil: Federico II" University of Naples, Department of Translational Medical Sciences, 80131 Naples, Italy sug: subj: Heart Failure Drug Therapy Heart Failure Complications Quality of Life Stroke Volume Heterocyclic Compounds Treatment Outcomes Drug Combinations Aminobutyric Acids Depression Drug Therapy Psychological Tests Human Clinical Assessment Tools ab: Background: Depression is highly prevalent in Heart Failure (HF). Treatment with sacubitril/valsartan improved quality of life and survival in HF patients. Aim of the study was to investigate prospectively the effect of sacubitril/valsartan on depression in advanced HF patients in waiting list for heart transplant (HT).Methods: 37 consecutive patients with advanced HF in waiting list for HT were treated with sacubitril/valsartan. We analyzed data derived from the assessment performed the year before the beginning of sacubitril/valsartan, at study entry, and at one year of follow-up. Depression was assessed with Beck Depression Inventory II (BDI) scale. Cognitive function were assessed with Mini-Mental State Examination (MMSE). Functioning was evaluated measuring meters at 6 Minute Walking Test (6MWT) and maximum rate of oxygen consumption (VO2 max).Results: At baseline, 64.9% of HF patients were in NYHA III and 35.1% NYHA IIIB, BDI was 15.2 ± 5.2 with 59.5% of patients with a score > 13. MMSE was 27.8 ± 2.6. After one year of follow-up NYHA class improved significantly, with 56.8% in NYHA II, 40.5% in NYHA III and 2.7% NYHA in IIIB (p < 0.001). VO2 max and 6MWT increased. Notably, BDI was 9.5 ± 3.9 with 21.6% of patients with a score > 13. MMSE remain stable (28.2 ± 2.1) (p = 0.104). No statistical differences are observed between data collected in the evaluation 1-year before and soon before treatment with sacubitril/valsartan. Multivariate regression analysis demonstrate a relationship between reduction in BDI-II score and improvement in six-minute walking test independently by the effect of sex, age, selective serotonin reuptake inhibitors, VO2 max, NT-proBNP, PAPs, NYHA class differences evaluated at follow-up versus baseline.Conclusions: Our study showed a reduction in depressive symptomatology in heart transplant waiting list patients treated with sacubitril/valsartan. The improvement in depressive symptomatology was paralleled by 6MWT increase in the follow-up. pubtype: Academic Journal doctype: research tables/charts Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|